Should we eradicate Helicobaster pylori infection in patients receiving nonsteroidal anti-inflammatory drugs or low-dose aspirin?

Chinese Journal of Digestive Diseases

Volumn 6, Issue 1, 2005, Pages 1-5

  Chan, Francis K L ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aspirin; Helicobacter pylori; Nonsteroidal anti inflammatory drugs (NSAIDs); Peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; BISMUTH; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; ROFECOXIB; ANTIINFECTIVE AGENT;

CLINICAL TRIAL; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; LOW DRUG DOSE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT FAILURE; ULCER HEALING; CHEMICALLY INDUCED DISORDER; MICROBIOLOGY; PATHOGENICITY; PATIENT SELECTION; STOMACH ULCER;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PATIENT SELECTION; RISK FACTORS; STOMACH ULCER;

EID: 16344386240     PISSN: 14439611     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2005.00192.x     Document Type: Review

References (32)

1. Menguy R, Desbaillets L. Role of inhibition of gastric mucous secretion in the phenomenon of gastric mucosal injury by indomethacin. Am J Dig Dis 1967; 12: 862-6.
2. Rainsford KD, Whithouse MW. Biochemical gastroprotection from acute ulceration induced by aspirin and related drugs. Biochem Pharmacol 1980; 29: 1281-9.
3. Sarosiek J, Mizuta K, Slomiany B. Effect of acetylsalicylic acid on gastric mucin activity, permeability to hydrogen ion, and susceptibility to pepsin. Biochem Pharmacol 1986; 35: 4291-5.
4. Sarosiek J, Slomiany A, Slomiany BL. Evidence for weakening of gastric mucus integrity by Camylobacter pylori. Scand J Gastroenterol 1988; 23: 585-90.
5. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 245-55.
6. Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727-34.
7. Yeomans ND, Tulassay Z, Juhasz L et al. Omeprazole compared with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 719-26.
8. Labenz J, Tillenburg B, Peitz U et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
9. Gillen D, Wirz AA, Neithercut WD, Ardill JES, McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
10. Chan FK, Sung JY, Chung SC et al. Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9.
11. Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002; 360: 933-41.
12. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and the risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
13. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM. H. pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther 2001; 15: 63-71.
14. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998; 352: 1016-21.
15. Griffin MR, Piper JM, Daugherty JR et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.
16. Gabriel SE, Jaakkimainen L, Bombardier C. Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96.
17. Langman MJS, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
18. Henry D, Lim LL, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
19. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
20. Chan FK. Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Gastroenterol Clin North Am 2001; 30 937-52.
21. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
22. Chan FK, Graham DY. Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications: review and recommendations based on risk assessment (Review Article). Aliment Pharmacol Ther 2004; 19: 1051-61.
23. Chan FK. Levofloxacin-based triple regimens were better than standard quadruple regimens for second-line eradication of Helicobacter pylori. Am Coll Physicians J Club 2004; 141: 19.
24. Chan FK, Sung JY, Suen R et al. Does eradication of H. pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998; 12: 1201-5.
25. Chan FK, Chung SCS, Suen BY et al. Prevention of recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking non-steroidal anti-inflammatory drugs. N Engl J Med 2001; 344: 967-73.
26. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8.
27. Hawkey GM, Stack WA, Pearson G, Everitt S, Logan RFA, Hawkey CJ. Non-steroidal anti-inflammatory drugs, aspirin and Helicobacter pylori as risk factors for bleeding peptic ulcers. Gut 1997; 41: A5.
28. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 245-55.
29. Goldstein JL, Correa P, Zhao WW et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-27.
30. Goldstein JL, Agrawal NM, Silverstein FE et al. Influence of H. pylori infection and/or low-dose aspirin on gastroduodenal ulceration in patients treated with placebo, celecoxib, or NSAIDs. Gastroenterology 1999; 116: A174.
31. Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 1006-12.
32. Chan FK. COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. Curr Pharm Des 2003; 9 2213-19.